USA's FDA QMSR Shockwave: Pure Global on Hidden Compliance Traps

The U.S. FDA has officially replaced its long-standing Quality System Regulation (QSR) with the new Quality Management System Regulation (QMSR), aligning with the global ISO 13485 standard. This landmark decision promises to streamline global compliance but introduces critical new challenges. This episode of MedTech Global Insights explores the real-world impact of this change. We move beyond the headlines to dissect the so-called "ISO 13485 plus" model, revealing the subtle but crucial FDA requirements that remain. Learn how to navigate the transition and avoid the hidden compliance traps that could derail your U.S. market strategy. **Case Study:** A device maker with full ISO 13485 certification believes they are ready for their next FDA inspection. However, they overlooked a specific FDA provision on complaint handling that was retained in the new QMSR. The result? A critical observation during their audit that puts their market access at risk, because they assumed harmonization meant 100% equivalence. **This episode will answer:** - What specific parts of the old QSR did the FDA keep in the new QMSR rule? - Is your current ISO 13485 certificate enough to pass an FDA inspection now? - What should be the number one priority in your gap analysis? - How does this change affect companies that only sell in the United States? - What are the biggest mistakes a company can make during this transition period? - How will the FDA's inspection approach change under the new QMSR? - What documentation needs immediate review and revision? - Does this harmonization make it easier or harder for startups to enter the US market? For more information, contact us at [email protected] or visit https://pureglobal.com/. For FREE AI tools and a comprehensive medical device database, visit https://pureglobal.ai/.